Skip to content

US · BTMD · MEDICAL - CARE FACILITIES

biote Corp. (BTMD) intrinsic value and stock valuation

$0.81as of 2026-11-21 · Mkt cap 99.68M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

biote Corp. DCF and intrinsic value

InvestorsCraft values BTMD with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BTMD’s statements →

biote Corp. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Care Facilities Irving, TX 75038 biote.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$192.2M+10.5% 5y CAGRd
20192025
Net income
$27.1M-1.5% 5y CAGRd
20192025
Free cash flow
$30.2M+3.8% 5y CAGRd
20192025
Total equity
-$-50.4M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$192.2M$197.2M$185.4M$165M$139.4M
Operating income$35.6M$31.6M$28.7M-$-60.72M$34.6M
Net income$27.1M$3.16M$3.32M-$-970K$32.6M
EPSd$737.7K$92.2K$129.1K-$-120.35K$4.31M
Operating cash flow$35.2M$45.2M$26.9M-$-9.16M$33.7M
Capital expenditure-$-5.01M-$-6.43M-$-2.71M-$-1.84M-$-3.81M
Free cash flow$30.2M$38.8M$24.2M-$-10.99M$29.9M
Total assets$107.6M$122.4M$155.3M$111.6M$54.3M
Total debt$109.9M$110.9M$114.9M$120.4M$37.3M
Net debt$85.8M$71.5M$25.9M$41.2M$10.6M
Total equity-$-50.4M-$-102.2M-$-36.55M-$-58.27M$4.12M
Cash and short-term investments$24.1M$39.3M$89M$79.2M$26.8M
Income statement
20252024202320222021
Revenue$192.2M$197.2M$185.4M$165M$139.4M
Cost of revenue$54.9M$58.1M$57.9M$54.6M$48.8M
Gross profit$137.4M$139.1M$127.5M$110.4M$90.6M
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$101.8M$107.5M$98.8M$171.1M$54M
Other expenses$0.00$0.00$0.00$0.00$2.06M
Operating expenses$101.8M$107.5M$98.8M$171.1M$56M
Cost and expenses$156.7M$165.6M$156.7M$225.7M$104.8M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$11M$11M$6.36M$4.05M$1.67M
Depreciation and amortization$3.67M$3.57M$790K$2.2M$1.4M
Ebitda$52.2M$15.6M$39.5M$7.96M$36M
Operating income$35.6M$31.6M$28.7M-$-60.72M$34.6M
Total other income/expenses, net$2.03M-$-30.59M-$-28.78M$62.4M-$-1.66M
Income before tax$37.6M$1.02M-$-120K$1.71M$32.9M
Income tax expense$5.99M$970K$2.68M$390K$290K
Net income$27.1M$3.16M$3.32M-$-970K$32.6M
Weighted average shares outstanding$31.3M$34.3M$25.7M$8.06M$7.57M
Weighted average diluted shares outstanding$36.7M$34.3M$25.7M$8.06M$7.57M
Balance sheet
20252024202320222021
Cash and short-term investments$24.1M$39.3M$89M$79.2M$26.8M
Net receivables$7.68M$7.7M$8.17M$6.95M$5.23M
Inventory$19.1M$14.9M$17.3M$11.2M$9.62M
Total current assets$54.7M$68.1M$122.3M$101.2M$47.1M
Property, plant and equipment, net$13.5M$10.2M$3.1M$3.56M$2.69M
Goodwill and intangible assets$10.1M$15.2M$4.97M$5.07M$4.55M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$52.9M$54.2M$33M$10.5M$7.25M
Total assets$107.6M$122.4M$155.3M$111.6M$54.3M
Accounts payable$6.83M$5.81M$4.16M$4.11M$4.35M
Short-term debt$6.84M$6.77M$6.56M$6.42M$5.25M
Deferred revenue$3.02M$2.96M$3M$1.97M$1.71M
Total current liabilities$45M$51.5M$22.2M$18.8M$17.3M
Long-term debt$103.1M$104.1M$108.3M$114M$32.1M
Deferred revenue, non-current$1.1M$1.55M$1.32M$930K$800K
Total non-current liabilities$113M$173.1M$169.6M$151.2M$32.9M
Capital lease obligations$2.89M$3.41M$1.99M$2.09M$380K
Total liabilities$158M$224.6M$191.8M$169.9M$50.2M
Common stock$0.00$0.00$10K$10K$0.00
Retained earnings-$-49.55M-$-100.3M-$-29.39M-$-44.46M$4.17M
Accumulated other comprehensive income (loss)-$-30K-$-40K-$-10K-$-10K-$-40K
Total equity-$-50.4M-$-102.2M-$-36.55M-$-58.27M$4.12M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$109.9M$110.9M$114.9M$120.4M$37.3M
Net debt$85.8M$71.5M$25.9M$41.2M$10.6M
Cash flow statement
20252024202320222021
Net income$27.1M$50K$3.32M$1.32M$32.6M
Depreciation and amortization$3.67M$3.57M$2.99M$2.2M$1.4M
Stock-based compensation$8.92M$8.73M$9.06M$82.2M$0.00
Change in working capital-$-8.25M$9.93M-$-8.93M-$-35.81M-$-1.46M
Accounts receivable-$-960K-$-2.27M-$-510K-$-1.56M-$-750K
Inventory-$-6.24M$3.71M-$-6.1M-$-1.71M-$-5.76M
Accounts payable$1.01M$1.54M-$-170K$420K$1.6M
Net cash provided by operating activities$35.2M$45.2M$26.9M-$-9.16M$33.7M
Investments in property, plant and equipment-$-5.01M-$-6.43M-$-360K-$-330K-$-1.45M
Acquisitions, net$0.00-$-11.84M$0.00$0.00$0.00
Net cash used for investing activities-$-6.86M-$-18.8M-$-2.71M-$-1.84M-$-3.81M
Common stock issued$370K$280K$140K$440K$0.00
Common stock repurchased-$-3.37M-$-5.6M$0.00-$-420K$0.00
Dividends paid-$-1.73M-$-4.74M-$-8.69M-$-12.89M-$-11.4M
Net cash used for financing activities-$-43.55M-$-76.08M-$-14.38M$63.5M-$-20.34M
Net change in cash-$-15.22M-$-49.66M$9.77M$52.5M$9.56M
Cash at end of period$24.1M$39.3M$89M$79.2M$26.8M
Operating cash flow$35.2M$45.2M$26.9M-$-9.16M$33.7M
Capital expenditure-$-5.01M-$-6.43M-$-2.71M-$-1.84M-$-3.81M
Free cash flow$30.2M$38.8M$24.2M-$-10.99M$29.9M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About biote Corp.

        Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.

        CEO
        Robert C. Peterson
        Employees
        223
        Beta
        1.66

        Explore

        Frequently asked questions

        What is the intrinsic value of biote Corp. (BTMD)?

        InvestorsCraft does not currently publish an intrinsic value for BTMD. How the IC value is calculated.

        Is BTMD undervalued?

        InvestorsCraft does not publish an undervaluation signal for BTMD at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.